Scholar Rock Holding Corporation (2QK.F)

Compare

34.40

0.00

(0.00%)

At close: March 3 at 4:43:32 PM GMT+1

Q4 2024 Scholar Rock Holding Corp Earnings Call

Q4 2024 Scholar Rock Holding Corp Earnings Call

Thomson Reuters StreetEvents 4 days ago

SRRK
Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass., February 27, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2024.

Business Wire 4 days ago

SRRK
Scholar Rock to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., February 25, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences:

Business Wire 6 days ago

SRRK
Is Scholar Rock Holding (SRRK) One of the Oversold Biotech Stocks to Buy Now?

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against other oversold biotech stocks to buy now. Biotech Sector Performance and Challenges in 2024: Biotechnology stocks are among the most volatile in the […]

Insider Monkey 7 days ago

SRRK
Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

CAMBRIDGE, Mass., February 21, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that it will present additional data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 16

Business Wire 10 days ago

SRRK
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., February 14, 2025--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 371,500 shares of its common stock to eleven newly hired employees, consisting of inducement stock options to

Business Wire 17 days ago

SRRK
Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

CAMBRIDGE, Mass., February 10, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its fourth quarter and full year 2024 financial results and provide a business update on Thursday, February 27, 2025, at 8:15am ET.

Business Wire 21 days ago

SRRK
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

CAMBRIDGE, Mass., January 29, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration (FDA) for apitegromab, a muscle-targeted therapy designed and developed to provide clinically meaningfu

Business Wire last month

SRRK
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

CAMBRIDGE, Mass., January 29, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that Lisa Wyman has been appointed to the new role of Chief Technical and Quality Officer (CTQO) to support the Company’s ongoing growth and evolution to becoming a fully integrated biopharma co

Business Wire last month

SRRK
Here’s Why Scholar Rock Holding Corporation (SRRK) Is Skyrocketing

We recently compiled a list of the Why These 24 Stocks Are Skyrocketing. In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against the other stocks. One of the strongest stock market anomalies is the momentum effect, which is the tendency of recent past winners to outperform […]

Insider Monkey last month

SRRK
Scholar Rock Highlights 2025 Strategic Priorities

CAMBRIDGE, Mass., January 08, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2025.

Business Wire last month

SRRK
Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., January 02, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 9:45 a.m. PT (12:45 p.m. ET).

Business Wire last month

SRRK
Why Is Scholar Rock Holding Corporation (SRRK) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against the other small-cap biotech stocks. Revolutionizing Healthcare and Economy: The Rapid Growth of Biotechnology The biotechnology sector is […]

Insider Monkey 2 months ago

SRRK
Top Midday Gainers

Scholar Rock (SRRK) shares were surging in afternoon trade after analysts at Wedbush and Truist Securities Monday raised their respective price targets for the biopharmaceutical company's stock.

PREMIUM
MT Newswires 3 months ago

SRRK

SKYT
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

On Monday, Biohaven Ltd. (NYSE:BHVN) updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy (SMA) and obesity. In the RESILIENT SMA study, taldefgrobep showed clinically meaningful improvements in motor function at all time points on the Motor Function Measurement-32 scale (MFM-32), but the treatment arm did not statistically separate on the primary outcome at 48 weeks compared to the placebo+standard of care (SOC) group. Also Read: Biohaven Stock Spikes After Drug Candida

Benzinga 3 months ago

SRRK

BHVN
Biohaven muscle drug misses goal of SMA study, but advances in obesity

The setback likely removes one competitor to an emerging spinal muscular atrophy medicine from Scholar Rock, but sets the stage for a pair of readouts with implications for weight loss research.

BioPharma Dive 3 months ago

SRRK
Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

Scholar Rock Holding Corp (SRRK) reports significant progress in its SAPPHIRE study and financial growth, setting the stage for future market expansion.

GuruFocus.com 3 months ago

SRRK
Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass., November 12, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the third quarter ended September 30, 2024.

Business Wire 3 months ago

SRRK
Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin

CAMBRIDGE, Mass., November 04, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced new preclinical data that support the potential of SRK-439, a highly selective investigational antimyostatin antibody, to increase lean mass and lower fat mass gain when taken with metformin. T

Business Wire 3 months ago

SRRK
Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

CAMBRIDGE, Mass., November 01, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024, at 8:15am ET.

Business Wire 3 months ago

SRRK

Performance Overview

Return	2QK.F	S&P 500
YTD	-18.48%	-0.54%
1-Year	+145.71%	+13.87%
3-Year	+132.43%	+34.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Scholar Rock Holding Corporation (2QK.F)

Q4 2024 Scholar Rock Holding Corp Earnings Call

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Scholar Rock to Participate in Upcoming Investor Conferences

Is Scholar Rock Holding (SRRK) One of the Oversold Biotech Stocks to Buy Now?

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Here’s Why Scholar Rock Holding Corporation (SRRK) Is Skyrocketing

Scholar Rock Highlights 2025 Strategic Priorities

Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Why Is Scholar Rock Holding Corporation (SRRK) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Top Midday Gainers

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

Biohaven muscle drug misses goal of SMA study, but advances in obesity

Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress

Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Performance Overview